MIRM

Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.

Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.

Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.

MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.